Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.30 (
PARP
)
13,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The Fas/APO-1/CD95 ligand (CD95L) and the recently cloned
TRAIL
ligand belong to the TNF-family and share the ability to induce apoptosis in sensitive target cells. Little information is available on the degree of functional redundancy between these two ligands in terms of target selectivity and intracellular signalling pathway(s). To address these issues, we have expressed and characterized recombinant mouse
TRAIL
. Specific detection with newly developed rabbit anti-
TRAIL
antibodies showed that the functional
TRAIL
molecule released into the supernatant of recombinant baculovirus-infected Sf9 cells is very similar to that associated with the membrane fraction of Sf9 cells. CD95L resistant myeloma cells were found to be sensitive to
TRAIL
, displaying apoptotic features similar to those of the CD95L- and
TRAIL
-sensitive T leukemia cells Jurkat. To assess if IL-1beta-converting enzyme (ICE) and/or ICE-related proteases (IRPs) (caspases) are involved in
TRAIL
-induced apoptosis of both cell types, peptide inhibition experiments were performed. The irreversible IRP/caspase-inhibitor Ac-YVAD-cmk and the reversible IRP/caspase-inhibitor Ac-DEVD-CHO blocked the morphological changes, disorganization of plasma membrane phospholipids, DNA fragmentation, and loss of cell viability associated with
TRAIL
-induced apoptosis. In addition, cells undergoing
TRAIL
-mediated apoptosis displayed cleavage of poly(ADP)-ribose polymerase (
PARP
) that was completely blocked by Ac-DEVD-CHO. These results indicate that
TRAIL
seems to complement the activity of the CD95 system as it allows cells, otherwise resistant, to undergo apoptosis triggered by specific extracellular ligands. Conversely, however, induction of apoptosis in sensitive cells by
TRAIL
involves IRPs/caspases in a fashion similar to CD95L. Thus, differential sensitivity to CD95L and
TRAIL
seems to map to the proximal signaling events associated with receptor triggering.
...
PMID:Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. 910 50
Expression and function of the
TRAIL
apoptotic pathway was investigated in normal and malignant breast epithelial cells. Glutathione-S-transferase (GST)-
TRAIL
extracellular domain fusion proteins were produced to analyze
TRAIL
-induced apoptosis. Only GST-
TRAIL
constructs containing regions homologous to the Fas self-association and ligand binding domains could induce apoptosis. GST-
TRAIL
induced significant (>90%) apoptosis in just one of eight normal and one of eight malignant breast cell lines. All other lines were relatively resistant to
TRAIL
-induced apoptosis. Activating
TRAIL
receptors DR4 and DR5 were expressed in all normal and malignant breast cell lines. The inhibitory receptor TRID was highly expressed in one of four normal and two of seven malignant breast cell lines. DR4, DR5, or TRID expression did not correlate with sensitivity to
TRAIL
-induced apoptosis. Incubation of cell lines with doxorubicin or 5-fluorouracil significantly augmented
TRAIL
-induced apoptosis in most breast cell lines. By fractional inhibition analysis, the toxicity of the combination of
TRAIL
and doxorubicin or 5-fluorouracil was synergistic compared with either agent alone. In contrast, melphalan and paclitaxel augmented
TRAIL
-induced apoptosis in few cell lines, and methotrexate did not augment it in any cell line. Augmentation of
TRAIL
-induced apoptosis by doxorubicin or 5-fluorouracil was mediated through caspase activation. This was evidenced by the fact that chemotherapy agents that synergized with
TRAIL
(e.g., doxorubicin) themselves caused cleavage of caspase-3 and poly(ADP-ribose) polymerase (
PARP
), and their toxicity was blocked by the caspase inhibitor Z-Val-Ala-Asp(OMe)-CH2 (ZVAD-fmk). The combination of
TRAIL
and doxorubicin caused significantly greater caspase-3 and
PARP
cleavage, and the combined toxicity also was inhibited by ZVAD-fmk. In contrast, chemotherapy agents that did not augment
TRAIL
-induced apoptosis (e.g., methotrexate) caused minimal caspase-3 and
PARP
cleavage by themselves, and their toxicity was not inhibited by ZVAD-fmk. These drugs also did not increase caspase-3 or
PARP
cleavage when combined with
TRAIL
. In summary, few breast cell lines are sensitive to
TRAIL
-induced apoptosis, and no difference in sensitivity is found between normal and malignant cell lines. Treatment with chemotherapy provides an approach to sensitize breast cancer cells to
TRAIL
-induced apoptosis.
...
PMID:Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. 997 25
Death receptors of the Tumor Necrosis Factor (TNF) family form membrane-bound self-activating signaling complexes that initiate apoptosis through cleavage of proximal caspases including CASP8 and 10. Here we show that overexpression of the cytoplasmic domain (CD) of the DR4
TRAIL
receptor (TNFRSF10A,
TRAIL
R1) in human breast, lung, and colon cancer cell lines, using an adenovirus vector (Ad-DR4-CD), leads to p53-independent apoptotic cell death involving cleavage of CASP8 and 10 proximally and CASP3, 6, and 7 distally. DR4-CD overexpression also leads to cleavage of poly(ADP-ribose) polymerase (
PARP
) and the DNA fragmentation factor (DFF45; ICAD). Importantly, normal lung fibroblasts are resistant to DR4-CD overexpression and show no evidence of
PARP
-, CASP8- or CASP3-cleavage despite similar levels of adenovirus-delivered DR4-CD protein as the cancer cells. These results suggest that DR4 may signal death through known caspases and that further studies are required to evaluate Ad-DR4-CD as a novel anti-cancer agent. Finally, we show that overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (CDKN1A), or its N-terminal 91 amino acids containing cell cycle-inhibitory activity, inhibits DR4-CD-dependent proximal caspase cleavage. The blockage of initiator caspase activation provides a novel insight into how p21 may suppress apoptosis and enhance cell survival.
...
PMID:p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. 1069 97
The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces apoptosis in several types of cancer cell. CD437 inhibited the growth of both androgen-dependent and -independent human prostate carcinoma (HPC) cells in a concentration-dependent manner by rapid induction of apoptosis. CD437 was more effective in killing androgen-independent HPC cells such as DU145 and PC-3 than the androgen-dependent LNCaP cells. The caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK blocked apoptosis induced by CD437 in DU145 and LNCaP cells, in which increased caspase-3 activity and
PARP
cleavage were observed, but not in PC-3 cells, in which CD437 did not induce caspase-3 activation and
PARP
cleavage. Thus, CD437 can induce either caspase-dependent or caspase-independent apoptosis in HPC cells. CD437 increased the expression of c-Myc, c-Jun, c-Fos, and death receptors DR4, DR5 and Fas. CD437's potency in apoptosis induction in the different cell lines was correlated with its effects on the expression of oncogenes and death receptors, thus implicating these genes in CD437-induced apoptosis in HPC cells. However, the importance and contribution of each of these genes in different HPC cell lines may vary. Because CD437 induced the expression of DR4, DR5 and Fas, we examined the effects of combining CD437 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (
TRAIL
) and Fas ligand, respectively, in HPC cells. We found synergistic induction of apoptosis, highlighting the importance of the modulation of these death receptors in CD437-induced apoptosis in HPC cells. This result also suggests a potential strategy of using CD437 with
TRAIL
for treatment of HPC. Oncogene (2000) 19, 4513 - 4522.
...
PMID:Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. 1100 24
In this study we sought to clarify the role of the proapoptotic potential of mitochondria in the death pathway emanating from the
TRAIL
(
APO-2L
) and CD95 receptors in pancreatic carcinoma cells. We focused on the role of the Bcl-2 family member Bcl-XL, using three pancreatic carcinoma cell lines as a model system, two of which have high (Panc-1, PancTuI) and one has low (Colo357) Bcl-XL expression. In these cell lines, the expression of Bcl-XL correlated with sensitivity to apoptosis induced by
TRAIL
or anti-CD95. Flow cytometric analysis revealed cell surface expression of TRAIL-R1 and TRAIL-R2 on PancTuI and Colo357, and TRAIL-R2 on Panc-1 cells. In Colo357 cells retrovirally transduced with Bcl-XL, caspase-8 activation in response to treatment with
TRAIL
or anti-CD95 antibody was not different from parental cells and EGFP-transfected controls, however, apoptosis was completely suppressed as measured by the mitochondrial transmembrane potential deltapsim, caspase-3 activity (
PARP
cleavage) and DNA-fragmentation. Inhibition of Bcl-XL function by overexpression of Bax or administration of antisense oligonucleotides against Bcl-XL mRNA resulted in sensitization of Panc-1 cells to
TRAIL
and PancTuI cells to anti-CD95 antibody-induced cell death. The results show that Bcl-XL can protect pancreatic cancer cells from CD95- and
TRAIL
-mediated apoptosis. Thus, in these epithelial tumour cells the mitochondrially mediated 'type II' pathway of apoptosis induction is not only operative regarding the CD95 system but also regarding the
TRAIL
system.
...
PMID:Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. 1111 25
The tumor necrosis factor (TNF) related apoptosis-inducing ligand (
TRAIL
or Apo2L) and its receptors are members of the tumor necrosis factor superfamily.
TRAIL
triggers apoptosis by binding to its two proapoptotic receptors DR4 and DR5, a process which is negatively regulated by binding of
TRAIL
to its two decoy receptors TRID and TRUNDD. Here, we show that
TRAIL
effectively induces apoptosis in H460 human non-small-cell lung carcinoma cells via cleavage of caspases 8, 9, 7, 3, and BID, release of cytochrome c from the mitochondria, and cleavage of poly (ADP-ribose) polymerase (
PARP
). However, overexpression of Bcl2 blocked
TRAIL
-induced apoptosis in H460 cells, which correlated with the Bcl2 protein levels. Importantly, the release of cytochrome c and cleavage of caspase 7 triggered by
TRAIL
were considerably blocked in Bcl2 overexpressing cells as compared to vector control cells. Moreover, inhibition of
TRAIL
-mediated cytochrome c release and caspase 7 activation by Bcl2 correlated with the inability of
PARP
to be cleaved and the inability of the Bcl2 transfectants to undergo apoptosis. Thus, these results suggest that Bcl2 can serve an anti-apoptotic function during
TRAIL
-dependent apoptosis by inhibiting the release of cytochrome c and activation of caspase 7, thereby blocking caspase 7-dependent cleavage of cellular substrates.
...
PMID:Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. 1116 90
TRAIL
causes apoptosis in numerous types of tumor cells. However, the mechanisms regulating
TRAIL
-induced apoptosis remain to be elucidated. We have investigated the role of PKC in regulating
TRAIL
-induced mitochondrial events and apoptosis in the Jurkat T cell line. We found a caspase-dependent decline in mitochondrial membrane potential and translocation of cytochrome c from mitochondria into the cytosol in response to
TRAIL
. Both these events were prevented by PKC activation. Moreover, PKC activation considerably reduced the activation of caspases,
PARP
cleavage and apoptosis when induced upon
TRAIL
treatment. MAPK activation was involved in the mechanism of PKC-mediated inhibition of
TRAIL
-induced cytochrome c release from mitochondria. Furthermore, inhibition of the MAPK pathway partially reversed the PKC-mediated inhibition of
TRAIL
-induced apoptosis. Besides, PKC activation may also inhibit the
TRAIL
-induced apoptosis through a MAPK-independent mechanism. Altogether, these results indicate a negative role of PKC in the regulation of apoptotic signals generated upon
TRAIL
receptor activation.
...
PMID:Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line. 1131 19
The tumor necrosis factor-related apoptosis-inducing ligand (
TRAIL
,
Apo-2L
) is a recently characterized member of the family of programmed cell death-inducing ligands that includes TNF-alpha and CD95L (FasL). It is well known that
TRAIL
binds to the death signaling receptors, DR4 and DR5, and initiates the
TRAIL
death pathway. Activation of this pathway, mediated through a caspase cascade, causes apoptosis. In this study, we hypothesized that oxidative stress facilitates
TRAIL
-induced apoptosis by promoting caspase activity through cytochrome c release from mitochondria. Human colorectal carcinoma CX-1 cells were treated with various concentrations of
TRAIL
(12.5-200 ng/ml) and/or sodium nitroprusside (SNP; 0.03-1 mM) for 12 h. SNP, a nitric oxide donor, which had little toxic effect by itself, enhanced
TRAIL
-induced cytotoxicity. For example,
TRAIL
-induced apoptosis (200 ng/ml) was increased by a factor of 2.5-fold in the presence of 1 mM SNP. The combined treatment also caused an increase in cytochrome c release, caspase-3 activity, and
PARP
cleavage. Overexpression of Bcl-2 completely blocked the SNP-promoting effects, but only moderately inhibited
TRAIL
-induced apoptosis. Similar results were observed in the presence of hydrogen peroxide or peroxynitrite. Taken together, the present studies suggest that SNP enhances
TRAIL
-induced cytotoxicity by facilitating the mitochondria-mediated caspase signal transduction pathway.
...
PMID:Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. 1131 91
TRAIL
, Tumor necrosis factor-related apoptosis-inducing ligand), a member of the TNF family, is known to be cytotoxic for a high proportion of tumor cell lines. However, successful application of
TRAIL
in tumor therapy may depend on finding other agents that can potentiate its antitumor effects. The present study showed that the cytostatic/cytotoxic
TRAIL
activity against U937 cells could be significantly augmented by proteasome inhibitor PSI, as revealed by MTT assay. Increased cytostatic/cytotoxic effect on U937 cells by
TRAIL
/PSI combined treatment was caused by apoptosis, as shown by an increased
PARP
cleavage rate.
TRAIL
/PSI did not affect the level of mRNA expression for
TRAIL
receptors (DR4, DR5, DcR1) and other apoptosis signal transduction molecules (TRADD, caspase-8).
...
PMID:Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. 1139 70
TRAIL
(TNF-related apoptosis-inducing ligand) induces apoptosis in susceptible cells by binding to death receptors 4 (DR4) and 5 (DR5).
TRAIL
preferentially induces apoptosis in transformed cells and the identification of mechanisms by which
TRAIL
-induced apoptosis can be enhanced may lead to novel cancer chemotherapeutic strategies. Here we show that reovirus infection induces apoptosis in cancer cell lines derived from human breast, lung and cervical cancers. Reovirus-induced apoptosis is mediated by
TRAIL
and is associated with the release of
TRAIL
from infected cells. Reovirus infection synergistically and specifically sensitizes cancer cell lines to killing by exogenous
TRAIL
. This sensitization both enhances the susceptibility of previously resistant cell lines to
TRAIL
-induced apoptosis and reduces the amount of
TRAIL
needed to kill already sensitive lines. Sensitization is not associated with a detectable change in the expression of
TRAIL
receptors in reovirus-infected cells. Sensitization is associated with an increase in the activity of the death receptor-associated initiator caspase, caspase 8, and is inhibited by the peptide IETD-fmk, suggesting that reovirus sensitizes cancer cells to
TRAIL
-induced apoptosis in a caspase 8-dependent manner. Reovirus-induced sensitization of cells to
TRAIL
is also associated with increased cleavage of
PARP
, a substrate of the effector caspases 3 and 7.
...
PMID:Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. 1168 70
1
2
3
4
5
6
7
8
9
10
Next >>